Chronic Obstructive Pulmonary Disease (COPD) Pipeline Landscape and Therapeutics Market Review H2 2016

Thursday, November 10, 2016 Respiratory Disease News
Email Print This Page Comment bookmark
Font : A-A+

PUNE, India, November 10, 2016 /PRNewswire/ -- adds "Chronic Obstructive Pulmonary Disease (COPD)

- Pipeline Review, H2 2016" to its store providing comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory), complete with analysis by stage of development, drug target, mechanism
of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Complete report on H2 2016 pipeline review of Chronic Obstructive Pulmonary Disease (COPD) with 172 market data tables and 16 figures, spread across 577 pages is available at .

Companies discussed in this Chronic Obstructive Pulmonary Disease (COPD) Pipeline Review, H2 2016 report include AB2 Bio Ltd., Abeona Therapeutics, Inc., Ache Laboratorios Farmaceuticos S/A, Achillion Pharmaceuticals, Inc., Adamis Pharmaceuticals Corporation, Advinus Therapeutics Ltd, AlgiPharma AS, Allinky Biopharma, Alteogen Inc., Amakem NV, Ampio Pharmaceuticals, Inc., Angion Biomedica Corp., Apellis Pharmaceuticals Inc, Aridis Pharmaceuticals LLC, Astellas Pharma Inc., AstraZeneca Plc, Asubio Pharma Co., Ltd., Axikin Pharmaceuticals, Inc., Bayer AG, Beech Tree Labs, Inc., Bioneer Corporation, Biotie Therapies Corp., Boehringer Ingelheim GmbH, C4X Discovery Holdings PLC, Carolus Therapeutics, Inc., Cellular Biomedicine Group, Inc., Chiesi Farmaceutici SpA, Circassia Pharmaceuticals Plc, CSL Limited, Cytokinetics, Inc., Daiichi Sankyo Company, Limited, Diffusion Pharmaceuticals Inc., Domainex Limited, Elsalys Biotech SAS, enGene, Inc, Errant Gene Therapeutics, LLC, F. Hoffmann-La Roche Ltd., Foresee Pharmaceuticals, LLC, Galapagos NV, Gilead Sciences, Inc., GlaxoSmithKline Plc, Hanmi Pharmaceuticals, Co. Ltd., iCeutica, Inc., InMed Pharmaceuticals Inc., Innate Pharma S.A., INVENT Pharmaceuticals, Inc., Invion Limited, Jiangsu Hansoh Pharmaceutical Co., Ltd., Johnson & Johnson, KaloBios Pharmaceuticals, Inc., Kissei Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Ligand Pharmaceuticals, Inc., Medestea Research & Production S.p.A., Merck & Co., Inc., Mereo Biopharma Group Plc, Meridigen Biotech Co., Ltd., Microbion Corporation, Novartis AG, Odan Laboratories Ltd., OPKO Health, Inc., Orion Oyj, Panmira Pharmaceuticals, LLC., Pfizer Inc., PharmaLundensis AB, Pharmaxis Limited, Pila Pharma AB, Polyphor Ltd., Promedior, Inc., ProMetic Life Sciences Inc., Proteostasis Therapeutics, Inc., Pulmagen Therapeutics LLP, Pulmatrix, Inc., Quark Pharmaceuticals, Inc., Re-Pharm Limited, Recipharm AB, Respira Therapeutics Inc, Respiratorius AB, rEVO Biologics, Inc., Rhizen Pharmaceuticals S.A., SATT North SAS, Selvita S.A., Seoul Pharma Co., Ltd., Spring Bank Pharmaceuticals, Inc., Stelic Institute & Co., Inc., sterna biologicals Gmbh & Co KG, Sucampo Pharmaceuticals, Inc., Sun Pharma Advanced Research Company Ltd., Sunovion Pharmaceuticals Inc., Synovo GmbH, Syntrix Biosystems, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., TGV-Laboratories, Therabron Therapeutics, Inc., Theravance Biopharma, Inc., Torrent Pharmaceuticals Limited, U.S. Stem Cell, Inc., Unizyme Laboratories A/S, Vectura Group Plc, Verona Pharma Plc, Vertex Pharmaceuticals Incorporated, Yuhan Corporation, Yungjin Pharm. Co., Ltd. and Zambon Company S.p.A.

Order a copy of this report @ .

The Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 1, 13, 40, 29, 81, 25 and 5 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 3 molecules, respectively for Chronic Obstructive Pulmonary Disease (COPD). Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Explore more reports on Pharmaceuticals.

About Us: is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact: Ritesh Tiwari 2nd floor, metropole, Next to inox theatre, Bund garden road, Pune-411001 Maharashtra, India. Tel: +1-888-391-5441

Connect With Us on:



Twitter: https: //

G+ / Google Plus:

RSS/Feeds: http: //

SOURCE RnR Market Research

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store